<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=28035"><dc:title>Prognostic impact of interleukin-27 in peripheral artery disease</dc:title><dc:creator>Kokalj,	Nataša	(Avtor)
	</dc:creator><dc:creator>Jug,	Borut	(Avtor)
	</dc:creator><dc:subject>peripheral artery disease</dc:subject><dc:subject>interleukin-27</dc:subject><dc:subject>endovascular revascularization</dc:subject><dc:subject>major adverse cardiovascular events</dc:subject><dc:subject>major adverse limb events</dc:subject><dc:description>Atherosclerosis is a progressive arterial disease characterized by chronic inflammation, with interleukin-27 (IL-27) implicated as both a pro- and anti-inflammatory cytokine. This prospective cohort study evaluated association of circulating IL-27 levels in peripheral artery disease patients undergoing elective endovascular revascularization, with major adverse cardiovascular events (MACE) and major adverse limb events (MALE) over a median follow-up of 311 days. Elevated IL-27 levels were significantly associated with increased risk of MACE and MALE in unadjusted analyses. After adjusting for established cardiovascular and PAD risk factors, IL-27 remained an independent predictor of MACE (HR 2.95; p = 0.039), but not MALE. These findings indicate that elevated IL-27 levels are associated with unfavourable long-term prognosis.</dc:description><dc:date>2025</dc:date><dc:date>2026-03-06 15:20:16</dc:date><dc:type>Neznano</dc:type><dc:identifier>28035</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
